Abingdon Health Plc (ABDXF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Abingdon Health Plc (ABDXF) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. La acción obtiene una puntuación de 54/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026Abingdon Health Plc (ABDXF) Resumen de Asistencia Médica y Tuberías
Abingdon Health Plc specializes in diagnostic device development, manufacturing, and distribution, focusing on rapid testing solutions like COVID-19 tests and nucleic acid lateral flow immunoassays. The company serves a global market, offering both product sales and contract services within the medical diagnostics industry.
Tesis de Inversión
Abingdon Health Plc presents a focused play on the diagnostics market, particularly in rapid testing solutions. With a market capitalization of $0.01 billion, the company's negative P/E ratio of -9.12 reflects current challenges in achieving profitability, despite a gross margin of 37.1%. Key value drivers include expansion of its contract manufacturing services and successful commercialization of its AppDx technology. Growth catalysts include potential partnerships and increased demand for rapid diagnostic solutions. Potential risks include competition from established players and the need to achieve sustainable profitability. Investors should monitor the company's ability to leverage its existing product portfolio and strategic collaborations to drive revenue growth and improve financial performance.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.01 billion indicates a small-cap company with potential for growth but also higher risk.
- Negative P/E ratio of -9.12 reflects current unprofitability, requiring careful monitoring of future earnings.
- Gross margin of 37.1% demonstrates the potential for profitability if operational efficiencies are improved.
- Beta of 0.18 suggests low volatility compared to the overall market, indicating a relatively stable stock.
- Collaboration with Abcam plc provides access to a broader market and enhances product development capabilities.
Competidores y Pares
Fortalezas
- Established expertise in lateral flow technology.
- Manufacturing capabilities for diagnostic devices.
- Collaboration with Abcam plc.
- Diverse product portfolio including COVID-19 tests.
Debilidades
- Negative P/E ratio indicating current unprofitability.
- Small market capitalization.
- Dependence on COVID-19 testing market.
- Limited brand recognition compared to larger competitors.
Catalizadores
- Upcoming: Potential new contract manufacturing agreements.
- Ongoing: Commercialization of AppDx technology.
- Ongoing: Expansion of diagnostic test portfolio.
- Ongoing: Strategic partnerships and collaborations.
- Ongoing: Geographic expansion into new markets.
Riesgos
- Potential: Intense competition from established diagnostic companies.
- Potential: Decline in demand for COVID-19 testing.
- Potential: Regulatory changes in the healthcare industry.
- Potential: Economic downturn affecting healthcare spending.
- Ongoing: Negative P/E ratio indicating current unprofitability.
Oportunidades de crecimiento
- Expansion of Contract Manufacturing Services: Abingdon Health can leverage its manufacturing capabilities to secure more contract manufacturing agreements with other healthcare companies. The global contract manufacturing market for medical devices is projected to reach $108.1 billion by 2027, presenting a significant opportunity for Abingdon Health to increase its revenue and profitability. Timeline: Ongoing.
- Commercialization of AppDx Technology: The AppDx technology, which transforms smartphones into lateral-flow readers, has the potential to disrupt the point-of-care diagnostics market. By partnering with healthcare providers and diagnostic test developers, Abingdon Health can drive adoption of AppDx and generate recurring revenue through software licenses and data analytics services. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Abingdon Health can pursue strategic partnerships and collaborations with other companies in the healthcare industry to expand its product portfolio and market reach. The collaboration with Abcam plc is a positive example, and further partnerships could accelerate growth. Timeline: Ongoing.
- Development of New Diagnostic Tests: Abingdon Health can invest in the development of new diagnostic tests for various diseases and conditions. The global diagnostics market is expected to reach $137.7 billion by 2028, driven by advancements in technology and increasing demand for personalized medicine. Timeline: Ongoing.
- Geographic Expansion: Abingdon Health can expand its operations into new geographic markets, particularly in developing countries where there is a growing need for affordable and accessible diagnostic tests. The company can leverage its existing product portfolio and manufacturing capabilities to establish a presence in these markets. Timeline: Ongoing.
Oportunidades
- Expansion of contract manufacturing services.
- Commercialization of AppDx technology.
- Development of new diagnostic tests.
- Geographic expansion into developing markets.
Amenazas
- Intense competition from established diagnostic companies.
- Decline in demand for COVID-19 testing.
- Regulatory changes in the healthcare industry.
- Economic downturn affecting healthcare spending.
Ventajas competitivas
- Proprietary lateral flow technology.
- Established manufacturing capabilities.
- Strategic collaboration with Abcam plc.
- Expertise in diagnostic test development.
Acerca de ABDXF
Abingdon Health Plc, incorporated in 2008 and headquartered in York, United Kingdom, operates within the medical diagnostics industry, focusing on the development, manufacture, and distribution of a range of diagnostic devices. The company's product portfolio includes the AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test, as well as nucleic acid lateral flow immunoassays, PCRD and PCRD FLEX for rapid readouts post isothermal amplification, the Abingdon Simply Test range of self-tests, and the 2019-nCoV Antigen Test for qualitative detection of antigens to SARS-CoV-2. Abingdon Health also offers AppDx, a customizable image capturing technology that transforms smartphones into lateral-flow readers. Beyond its proprietary products, Abingdon Health provides contract manufacturing, nucleic acid lateral flow test customization, and lateral flow development and manufacturing services. The company extends its expertise through consultancy services to businesses operating in the healthcare technology sector. Abingdon Health has a collaboration and co-marketing agreement with Abcam plc, enhancing its market reach and product development capabilities.
Qué hacen
- Develops rapid diagnostic tests for infectious diseases.
- Manufactures lateral flow immunoassays.
- Offers COVID-19 antibody and antigen tests.
- Provides contract manufacturing services for diagnostic devices.
- Offers a smartphone-based lateral flow reader technology (AppDx).
- Provides consultancy services to healthcare technology businesses.
Modelo de Negocio
- Sales of rapid diagnostic tests (e.g., COVID-19 tests).
- Contract manufacturing for other diagnostic companies.
- Licensing and sales of AppDx technology.
- Consultancy services for healthcare businesses.
Contexto de la Industria
Abingdon Health Plc operates in the medical diagnostics industry, a sector characterized by continuous innovation and increasing demand for rapid and accurate testing solutions. The market is driven by factors such as the growing prevalence of infectious diseases, the increasing adoption of point-of-care diagnostics, and advancements in biotechnology. Competitors include companies like CRPOF (CareRx Corporation), EIGRQ (Eurofins Scientific SE), MNNDF (MIND Technology, Inc.), NOXOF (Noxopharm Ltd), and PXXLF (Pro-Dex, Inc.). Abingdon Health's focus on lateral flow technology positions it to capitalize on the demand for rapid and cost-effective diagnostic tests.
Clientes Clave
- Healthcare providers (hospitals, clinics).
- Diagnostic test developers.
- Pharmaceutical companies.
- Research institutions.
Finanzas
Gráfico e información
Precio de la acción de Abingdon Health Plc (ABDXF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para ABDXF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ABDXF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ABDXF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ABDXF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Christopher William Hand
CEO
Christopher William Hand serves as the CEO of Abingdon Health Plc, managing a team of 113 employees. His background includes extensive experience in the healthcare and diagnostics industries. Prior to joining Abingdon Health, he held leadership positions at various companies, focusing on commercial strategy, product development, and market expansion. He brings a wealth of knowledge in driving growth and innovation within the healthcare sector.
Historial: Under Christopher William Hand's leadership, Abingdon Health has focused on expanding its product portfolio and strengthening its manufacturing capabilities. Key achievements include securing strategic collaborations and launching new diagnostic tests. He has overseen the development and commercialization of the AppDx technology, as well as navigated the company through the challenges and opportunities presented by the COVID-19 pandemic.
Información del mercado OTC de ABDXF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Abingdon Health Plc may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price volatility.
- Lack of regulatory oversight.
- Higher risk of fraud or manipulation.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's OTC Markets profile and disclosure status.
- Check for any regulatory actions or legal proceedings against the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Established manufacturing capabilities.
- Collaboration with Abcam plc.
- Development of proprietary technology (AppDx).
- Operating history since 2008.
- CEO with experience in the healthcare industry.
Acciones de Abingdon Health Plc: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar ABDXF?
Abingdon Health Plc (ABDXF) actualmente tiene una puntuación IA de 54/100, indicando puntuación moderada. Fortaleza clave: Established expertise in lateral flow technology.. Riesgo principal a monitorear: Potential: Intense competition from established diagnostic companies.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ABDXF?
ABDXF actualmente puntúa 54/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ABDXF?
Los precios de ABDXF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ABDXF?
La cobertura de analistas para ABDXF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ABDXF?
Las categorías de riesgo para ABDXF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition from established diagnostic companies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ABDXF?
La relación P/E para ABDXF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ABDXF sobrevalorada o infravalorada?
Determinar si Abingdon Health Plc (ABDXF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ABDXF?
Abingdon Health Plc (ABDXF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- OTC market data may be limited or delayed.
- AI analysis pending for ABDXF.